A Double-blind, Randomized, Stratified Multi-center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza

Trial Profile

A Double-blind, Randomized, Stratified Multi-center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Oseltamivir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 19 May 2017 Status changed from recruiting to completed.
    • 29 Apr 2017 Planned number of patients changed from 225 to 230.
    • 19 Jan 2017 Planned number of patients changed from 205 to 225.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top